Product Name:    Pimavanserin

Synonyms:    Pimavanserin;PIMAVANSERIN/1-(4-FLUOROBENZYL)-3-(4-ISOBUTOXYBENZYL)-1-(1-METHYLPIPERIDIN-4-YL)UREA;Unii-jz963p0dik;Pimavamserin;1-[(4-fluorophenyl)Methyl]-1-(1-Methylpiperidin-4-yl)-3-{[4-(2-Methylpropoxy)phenyl]Methyl}urea;N-(4-Fluorobenzyl)-N-(1-Methylpiperidin-4-yl)-N'-[[4-(2-Methylpropyloxy)phenyl]Methyl]carbaMide;N-[(4-Fluorophenyl)Methyl]-N-(1-Methyl-4-piperidinyl)-N'-[[4-(2-Methylpropoxy)phenyl]Methyl]urea;Urea,N-[(4-fluorophenyl)Methyl]-N-(1-Methyl-4-piperidinyl)-N'-[[4-(2-Methylpropoxy)phenyl]Methyl]-

CAS:    706779-91-1

MF:    C25H34FN3O2

MW:    427.55

EINECS:    1806241-263-5

Product Categories:    Intermediates & Fine Chemicals;Pharmaceuticals;Inhibitors

Pimavanserin is a kind of novel oral administrated drug for treatment of Parkinson's psychosis developed by Acadia pharmaceutical Company (US) with the trade name being Pimavanserin. In September 3rd 2014, it has been granted by the US Food and Drug Administration (FDA) for breakthrough therapy certification. Breakthrough therapy certification is created by the FDA for accelerating the development and review of new drugs for treatment of serious or life-threatening diseases.